Evidence map›Paper›PMID 27185794›Full record

ArticleAntimicrobial agents and chemotherapy2016

Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia.

Lina Zuluaga-Idárraga, Silvia Blair, Sheila Akinyi Okoth, Venkatachalam Udhayakumar, Paula L Marcet, Ananias A Escalante, Neal Alexander, Carlos Rojas

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Frequent and genetically diverseResearch square · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Recurrence inF1000Research · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Lina Zuluaga-IdárragaGrupo Malaria, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia linazulu83@gmail.com.
Silvia BlairGrupo Malaria, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Sheila Akinyi OkothDivision Parasitic Diseases and Malaria, Malaria Branch, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA Atlanta Research and Education Foundation, Atlanta, Georgia, USA.
Venkatachalam UdhayakumarDivision Parasitic Diseases and Malaria, Malaria Branch, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Paula L MarcetDivision of Parasitic Diseases and Malaria, Entomology Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ananias A EscalanteInstitute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Neal AlexanderMRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Carlos RojasGrupo de Epidemiologia, Facultad Nacional de Salud Pública, Universidad de Antioquia, Medellín, Colombia.
Universidad de Antioquia · CODivision of Parasitic Diseases and Malaria · USCenters for Disease Control and Prevention · USLondon School of Hygiene & Tropical Medicine · GBTemple University · US

Funding

Medical Research Council MR/K012126/1
6 · The paper itself

Abstract

Plasmodium vivax recurrences help maintain malaria transmission. They are caused by recrudescence, reinfection, or relapse, which are not easily differentiated. A longitudinal observational study took place in Turbo municipality, Colombia. Participants with uncomplicated P. vivax infection received supervised treatment concomitantly with 25 mg/kg chloroquine and 0.25 mg/kg/day primaquine for 14 days. Incidence of recurrence was assessed over 180 days. Samples were genotyped, and origins of recurrences were established. A total of 134 participants were enrolled between February 2012 and July 2013, and 87 were followed for 180 days, during which 29 recurrences were detected. The cumulative incidence of first recurrence was 24.1% (21/87) (95% confidence interval [CI], 14.6 to 33.7%), and 86% (18/21) of these events occurred between days 51 and 110. High genetic diversity of P. vivax strains was found, and 12.5% (16/128) of the infections were polyclonal. Among detected recurrences, 93.1% (27/29) of strains were genotyped as genetically identical to the strain from the previous infection episode, and 65.5% (19/29) of infections were classified as relapses. Our results indicate that there is a high incidence of P. vivax malaria recurrence after treatment in Turbo municipality, Colombia, and that a large majority of these episodes are likely relapses from the previous infection. We attribute this to the primaquine regimen currently used in Colombia, which may be insufficient to eliminate hypnozoites.

Indexed as

AntimalarialsChloroquineColombiaHumansKaplan-Meier EstimateMalaria, VivaxPlasmodium vivaxPrimaquineProspective StudiesAntimalarialsChloroquinePrimaquine

Identifiers

PMID27185794
PMCPMC4958195
OpenAlexW2494577270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.